Immunome reported net income of -$73.13M for the quarter ended Jun 2026. This income statement covers 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||||||||||||||
| Revenue | 2.36M | 4.26M | 3.56M | 3.83M | 1.03M | 2.36M | 2.91M | 2.74M | 2.93M | 4.01M | ||||||||||||||||||
| Operating items | ||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 4.51M | 4.38M | 8.08M | 5.72M | 5.22M | 4.25M | 3.91M | 5.72M | 3.82M | 9.64M | 15.37M | 29.08M | 37.20M | 47.89M | 36.87M | 40.45M | 49.19M | 50.77M | 46.38M | 59.88M | ||||||||
| Selling, General & AdministrativeSG&A | 3.21M | 3.46M | 3.58M | 3.21M | 3.31M | 3.54M | 2.92M | 4.32M | 4.38M | 8.04M | 6.00M | 6.98M | 9.53M | 10.45M | 10.69M | 10.04M | 10.95M | 12.09M | 12.95M | 18.25M | ||||||||
| Other Operating ExpensesOther Opex | 80.80M | 111.95M | 6.31M | 6.71M | 27.37M | 10.00M | ||||||||||||||||||||||
| Operating ExpensesOpex | 7.72M | 7.84M | 11.65M | 8.93M | 8.53M | 7.79M | 6.83M | 10.04M | 8.20M | 98.48M | 133.33M | 42.37M | 53.43M | 85.71M | 47.56M | 50.49M | 60.14M | 72.86M | 59.33M | 78.14M | ||||||||
| Operating IncomeOp. Inc | -7.72M | -7.84M | -11.65M | -8.93M | -8.53M | -7.79M | -4.47M | -5.77M | -4.63M | -94.65M | -132.30M | -40.01M | -50.52M | -82.97M | -44.64M | -46.48M | -60.14M | -72.86M | -59.33M | -78.14M | ||||||||
| EBIT | -7.72M | -7.84M | -11.65M | -8.93M | -8.53M | -7.79M | -4.47M | -5.77M | -4.63M | -94.65M | -132.30M | -40.01M | -50.52M | -82.97M | -44.64M | -46.48M | -60.14M | -72.86M | -59.33M | -78.14M | ||||||||
| Non-operating items | ||||||||||||||||||||||||||||
| Non Operating Interest Expenses | ||||||||||||||||||||||||||||
| Net income details | ||||||||||||||||||||||||||||
| EBT | -7.72M | -7.84M | -11.65M | -8.93M | -8.53M | -7.79M | -4.47M | -5.77M | -4.63M | -94.65M | -132.30M | -40.01M | -50.52M | -82.97M | -44.64M | -46.48M | -60.14M | -72.86M | -59.33M | -78.14M | ||||||||
| Profit After TaxPAT | -7.72M | -7.81M | -11.70M | -8.92M | -8.53M | -8.41M | -4.27M | -5.56M | -4.34M | -92.63M | -129.49M | -36.12M | -47.10M | -80.25M | -41.64M | -43.40M | -57.46M | -69.90M | -53.84M | -73.13M | ||||||||
| Income from Continuing OperationsIncome (Continuing) | -7.72M | -7.84M | -11.65M | -8.93M | -8.53M | -7.79M | -4.47M | -5.77M | -4.63M | -94.65M | -132.30M | -40.01M | -50.52M | -82.97M | -44.64M | -46.48M | -60.14M | -72.86M | -59.33M | -78.14M | ||||||||
| Consolidated Net IncomeConsol Net Inc. | -7.72M | -7.84M | -11.65M | -8.93M | -8.53M | -7.79M | -4.47M | -5.77M | -4.63M | -94.65M | -132.30M | -40.01M | -50.52M | -82.97M | -44.64M | -46.48M | -60.14M | -72.86M | -59.33M | -78.14M | ||||||||
| Income towards Parent CompanyParent Net Inc | -7.72M | -7.84M | -11.65M | -8.93M | -8.53M | -7.79M | -4.47M | -5.77M | -4.63M | -94.65M | -132.30M | -40.01M | -50.52M | -82.97M | -44.64M | -46.48M | -60.14M | -72.86M | -59.33M | -78.14M | ||||||||
| Preferred Dividend PaymentsPref Dividends | 0.62M | |||||||||||||||||||||||||||
| Net Income towards Common StockholdersNet Income | -7.72M | -7.85M | -11.65M | -8.93M | -9.15M | -7.79M | -4.47M | -5.77M | -4.34M | -92.63M | -132.30M | -40.01M | -50.52M | -82.97M | -44.64M | -46.48M | -60.14M | -72.86M | -59.33M | -78.14M | ||||||||
| Additional items | ||||||||||||||||||||||||||||
| EPS (Basic) | -0.65 | -0.68 | -0.96 | -0.74 | -0.75 | -0.64 | -0.37 | -0.47 | -0.36 | -4.67 | -2.57 | -0.67 | -0.84 | -1.41 | -0.56 | -0.53 | -0.68 | -0.83 | -0.52 | -0.69 | ||||||||
| EPS (Diluted) | -0.65 | -0.68 | -0.96 | -0.74 | -0.75 | -0.64 | -0.37 | -0.47 | -0.36 | -4.67 | -2.57 | -0.67 | -0.84 | -1.41 | -0.56 | -0.53 | -0.68 | -0.83 | -0.52 | -0.69 | ||||||||
| Shares Outstanding | 11.93M | 11.54M | 12.12M | 12.13M | 12.13M | 12.13M | 12.18M | 12.20M | 12.20M | 19.84M | 51.54M | 59.94M | 60.21M | 58.64M | 79.41M | 87.01M | 87.96M | 87.35M | 113.14M | 113.27M | ||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 11.93M | 11.54M | 12.12M | 12.13M | 12.13M | 12.13M | 12.18M | 12.20M | 12.20M | 19.84M | 51.54M | 59.94M | 60.21M | 58.64M | 79.41M | 87.01M | 87.96M | 87.35M | 113.14M | 113.27M | ||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 12.09M | 12.11M | 12.13M | 12.13M | 12.13M | 12.13M | 12.19M | 12.20M | 12.20M | 19.84M | 59.69M | 60.01M | 60.42M | 64.46M | 86.96M | 87.01M | 91.71M | 87.35M | 113.17M | 113.40M | ||||||||
| EBITDA | -7.72M | -7.84M | -11.65M | -8.93M | -8.53M | -7.79M | -4.47M | -5.77M | -4.63M | -94.65M | -132.30M | -40.01M | -50.52M | -82.97M | -44.64M | -46.48M | -60.14M | -72.86M | -59.33M | -78.14M | ||||||||
| Interest ExpensesInt Expense |